LGND Ligand Pharmaceuticals
Price Chart
Executive Summary
Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, marking the first approved therapy for this condition. Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI, which expands its commercial potential beyond IgA nephropathy and positions it as a key driver of future royalty growth.
Actionable Insight
Traders should monitor FILSPARI's commercial uptake in FSGS, as the expanded indication significantly increases the addressable market and royalty stream for Ligand; the 9% royalty on a growing sales base could drive outsized revenue growth if adoption accelerates.
Key Facts
- FDA approved FILSPARI for FSGS in patients aged 8+ without nephrotic syndrome, the first and only approved treatment for this indication.
- Ligand receives a 9% royalty on worldwide net sales of FILSPARI, which is already the most prescribed FDA-approved drug for IgA nephropathy.
- Phase 3 DUPLEX study showed a 46% reduction in proteinuria overall and 48% in non-nephrotic syndrome patients, with statistically significant results.
- Addressable U.S. population estimated at over 30,000 patients with FSGS without nephrotic syndrome.
- FILSPARI has a dual mechanism targeting endothelin A and angiotensin II receptors, offering kidney protection.
Financial Impact
High incremental royalty revenue potential from expanded indication; FILSPARI now addresses a second rare kidney disease with significant unmet need.
Risk Factors
- Commercial execution risk: Market penetration and reimbursement for the new FSGS indication may lag expectations.
- Regulatory and clinical risk: Future safety findings or label restrictions could limit use.
- Competition risk: Emerging therapies for FSGS could challenge FILSPARI's dominance.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273192 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 1, 2026
5w ago
|
Insider Cluster
| $227.44 $229.78 | ▲ +1.03% | ▼ −4.26% | $237.75 (+4.53%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $232.34 $220.48 | ▼ −5.10% | ▼ −11.40% | $237.75 (+2.33%) |
|
Feb 26, 2026
14w ago
|
8-K
| $196.17 $203.70 | ▲ +3.84% | ▲ +10.24% | $237.75 (+21.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access